Bal Pharma (BALPHARMA) | Stock Overview & Key Data
Bal Pharma Performance Comparison
Stock Range
Today's Range
Low: ₹83.01
High: ₹84.89
on October 3, 2025
52 Week Range
Low: ₹78.06
High: ₹140.95
on March 4, 2025
on November 22, 2024
All-Time High: ₹167.90 on January 11, 2016
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR1.4B
EPS
4.51
P/E Ratio (TTM)
18.82
Forward P/E
N/A
P/B Ratio
2.17
PEG Ratio
-1.00
Div. Yield
1.20%
ROE
9.32%
Beta
0.184
Debt to Equity
196.55
Financial Highlights
Profitability
Gross Margin
49.08%
Operating Margin
5.37%
Profit Margin
2.43%
Returns and Earnings
Return on Assets (TTM)
2.15%
Return on Equity (TTM)
9.32%
EBITDA
INR289.3M
Net Income (TTM)
INR71.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR185.04
Quarterly Revenue Growth (YoY)
-11.40%
Quarterly Earnings Growth (YoY)
-22.60%
Dividend Information
Last 12-Month Dividend
₹1.20
Current Dividend Yield
1.20%
3-Year Average Dividend Yield
1.01%
3-Year Average Annual Dividend
₹1.07
3-Year Total Dividends
₹3.20
Ex-Dividend Date
September 17, 2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Bal Pharma BALPHARMA | 1.37B Small-cap | -1.89% | -5.49% | -17.78% | -6.87% | -33.49% | -36.30% | -11.41% | 27.35% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 0.56% | 4.66% | -1.86% | -3.66% | -13.43% | -14.34% | 71.30% | 219.01% |
| Divi's Laboratories DIVISLAB | 1.57T Large-cap | -4.58% | -6.29% | -16.72% | 2.89% | -5.98% | 5.24% | 52.85% | 79.00% |
| Suven Life Sciences SUVEN | 48.20B Small-cap | -6.65% | -0.56% | -18.38% | 69.66% | 61.86% | 45.66% | 184.80% | 304.79% |
| Sequent Scientific SEQUENT | 48.13B Small-cap | -8.42% | 9.29% | -3.35% | 37.17% | 0.89% | -10.14% | 69.59% | 19.72% |
| Aarti Drugs AARTIDRUGS | 44.55B Small-cap | -5.64% | 3.08% | 3.92% | 42.25% | 7.15% | -5.48% | -1.60% | -50.42% |
Ownership & Short Interest
Insider Ownership
65.46%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
39K
Average 90-Day Volume
28K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BALPHARMA's 52-week high and low?
- In the last 52 weeks, Bal Pharma reached a high of ₹140.95 (on November 22, 2024) and a low of ₹78.06 (on March 4, 2025).
- What is the market cap and P/E ratio for BALPHARMA?
- Curious about Bal Pharma's size and valuation? Its market capitalization stands at 1.37B. When it comes to valuation, the P/E ratio (trailing twelve months) is 18.82, and the forward P/E (looking ahead) is N/A.
- Does BALPHARMA pay dividends? If so, what's the yield?
- Yes, Bal Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.20%, and the company has paid an average of ₹1.07 per share annually over the past 3 years.
- Who are Bal Pharma's main competitors or similar companies to consider before investing?
When looking at Bal Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.34% 71.30% Divi's Laboratories
DIVISLAB1.57T Healthcare Drug Manufacturers - Specialty & Generic 5.24% 52.85% Suven Life Sciences
SUVEN48.20B Healthcare Drug Manufacturers - Specialty & Generic 45.66% 184.80% Sequent Scientific
SEQUENT48.13B Healthcare Drug Manufacturers - Specialty & Generic -10.14% 69.59% Aarti Drugs
AARTIDRUGS44.55B Healthcare Drug Manufacturers - Specialty & Generic -5.48% -1.60% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Bal Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Bal Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 9.32%, the Debt to Equity ratio from the most recent quarter is 196.55, and its Gross Profit Margin stands at 49.08%.
- What is the recent revenue and earnings growth for BALPHARMA?
- Looking at Bal Pharma's growth, its revenue over the trailing twelve months (TTM) was INR3B. Compared to the same quarter last year (YoY), quarterly revenue grew by -11.40%, and quarterly earnings saw a YoY growth of -22.60%.
- How much of BALPHARMA stock is held by insiders and institutions?
- Wondering who owns Bal Pharma stock? Company insiders (like executives and directors) hold about 65.46% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.